Pliant Therapeutics Inc.

# Signal Note: Redmile Group Initiates PLRX Position Redmile's $2.0M entry into Pliant suggests conviction in the company's lead program, PLN-74809, a hepatic-selective FXR agonist for NASH that completed a Phase 2b study with topline results expected in 2H 2024. The timing and size indicate confidence in either the upcoming data readout or near-term partnership potential, as NASH therapeutics remain undersaturated despite high unmet need. Green's healthcare crossover expertise typically signals focus on commercial inflection points rather than early-stage science.